Tolerability Overview
Retatrutide's adverse event profile is consistent with the GLP-1 receptor agonist class — dominated by gastrointestinal effects that are dose-dependent and most pronounced during dose escalation. The compound's additional glucagon receptor agonism introduces one distinct finding not seen with Tirzepatide or semaglutide: a modest but consistent resting heart rate increase.
Phase 2 TRIUMPH-1 (NEJM, 2023) provided the primary published safety dataset across dose tiers from 1mg to 12mg weekly. Phase 3 TRIUMPH-4 (Dec 2025) confirmed the Phase 2 tolerability profile at scale over 68 weeks.
Gastrointestinal Side Effects
GI adverse events are the most common effects across all dose tiers. The rates below reflect the 12mg weekly group from Phase 2 TRIUMPH-1 — the worst-case profile. Rates are substantially lower at 1mg, 4mg, and 8mg doses, and attenuate over time during the maintenance phase.
Source: Phase 2 TRIUMPH-1 (NEJM 2023), 12mg/week dose group. Rates lower at 1mg, 4mg, 8mg doses.
GI effects peak during dose escalation (typically weeks 1–16) and attenuate substantially in the maintenance phase. The 6–16% dropout rate in Phase 2 was primarily GI-driven and concentrated in the higher dose groups.
Cardiovascular Observations
The most clinically noteworthy signal unique to Retatrutide — not observed to the same degree with dual agonists — is a modest but consistent elevation in resting heart rate, attributed to glucagon receptor agonism.
Heart Rate Elevation vs. Comparable Agents
| Compound | Mechanism | Mean HR Increase |
|---|---|---|
| Retatrutide | GLP-1 + GIP + Glucagon | +5 bpm |
| Tirzepatide | GLP-1 + GIP | +2 bpm |
| Semaglutide | GLP-1 | +2 bpm |
The ~4–6 bpm increase was dose-dependent and most prominent in the 8mg and 12mg groups. The TRIUMPH-CV trial (ongoing) is specifically designed to evaluate long-term cardiovascular implications. Blood pressure and lipid profiles showed favorable (beneficial) changes across all dose groups.
Discontinuation Rates by Dose
| Dose (weekly) | Dropout Rate | Primary Reason |
|---|---|---|
| Placebo | ~0% | — |
| 1 mg | ~6% | GI adverse events |
| 4 mg | ~8% | GI adverse events |
| 8 mg | ~12% | GI + HR elevation |
| 12 mg | ~16% | GI adverse events |
For context, Tirzepatide's Phase 3 SURMOUNT-1 reported ~7.1% discontinuation at 15mg. Retatrutide's 12mg group at ~16% suggests the highest dose tier is less well-tolerated — consistent with the additional receptor mechanism load.
Side Effect Profile vs. Tirzepatide
| Effect | Retatrutide 12mg | Tirzepatide 15mg |
|---|---|---|
| Nausea | ~57% | ~42% |
| Vomiting | ~28% | ~21% |
| Diarrhea | ~25% | ~26% |
| Constipation | ~22% | ~24% |
| Heart rate ↑ | +5 bpm | +2 bpm |
| Discontinuation | ~16% | ~7% |
| Blood pressure | ↓ Favorable | ↓ Favorable |
Additional Adverse Events
| Event | Frequency | Notes |
|---|---|---|
| Injection site reactions | ~8–12% | Erythema, swelling; resolved without intervention |
| Fatigue / asthenia | ~11% | Most common during dose escalation |
| Headache | ~9% | Mild; class-consistent |
| Pancreatitis | <1% | Rare; consistent with incretin class |
| Gallbladder events | ~2% | Consistent with rapid weight loss; class effect |
| Hypoglycemia | <2% | Glucose-dependent mechanism; low risk in isolation |